155 related articles for article (PubMed ID: 37708925)
1. Functional insulin aspart/insulin degludec-based microneedles for promoting postprandial glycemic control.
Chen BZ; Li WX; Feng YH; Zhang XP; Jiao J; Li ZL; Nosrati-Siahmazgi V; Shahbazi MA; Guo XD
Acta Biomater; 2023 Nov; 171():350-362. PubMed ID: 37708925
[TBL] [Abstract][Full Text] [Related]
2. Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin.
Chen MC; Ling MH; Kusuma SJ
Acta Biomater; 2015 Sep; 24():106-16. PubMed ID: 26102333
[TBL] [Abstract][Full Text] [Related]
3. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin.
Liu S; Jin MN; Quan YS; Kamiyama F; Katsumi H; Sakane T; Yamamoto A
J Control Release; 2012 Aug; 161(3):933-41. PubMed ID: 22634072
[TBL] [Abstract][Full Text] [Related]
4. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
7. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
[TBL] [Abstract][Full Text] [Related]
9. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
10. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
11. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of composite microneedles integrated with insulin-loaded CaCO
Liu D; Yu B; Jiang G; Yu W; Zhang Y; Xu B
Mater Sci Eng C Mater Biol Appl; 2018 Sep; 90():180-188. PubMed ID: 29853081
[TBL] [Abstract][Full Text] [Related]
13. Fabrication of biodegradable composite microneedles based on calcium sulfate and gelatin for transdermal delivery of insulin.
Yu W; Jiang G; Liu D; Li L; Chen H; Liu Y; Huang Q; Tong Z; Yao J; Kong X
Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():725-734. PubMed ID: 27987766
[TBL] [Abstract][Full Text] [Related]
14. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H; Heise T
Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789
[TBL] [Abstract][Full Text] [Related]
15. Dissolving Polymer Microneedles for Transdermal Delivery of Insulin.
Zhang N; Zhou X; Liu L; Zhao L; Xie H; Yang Z
Front Pharmacol; 2021; 12():719905. PubMed ID: 34630098
[TBL] [Abstract][Full Text] [Related]
16.
Tort S; Mutlu Agardan NB; Han D; Steckl AJ
J Microencapsul; 2020 Nov; 37(7):517-527. PubMed ID: 32783663
[TBL] [Abstract][Full Text] [Related]
17. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
[TBL] [Abstract][Full Text] [Related]
19. Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats.
Ling MH; Chen MC
Acta Biomater; 2013 Nov; 9(11):8952-61. PubMed ID: 23816646
[TBL] [Abstract][Full Text] [Related]
20. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Senior P; Hramiak I
Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
